12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Emixustat hydrochloride: Phase IIb/III started

Acucela began the double-blind, placebo-controlled Phase IIb/III SEATTLE trial to evaluate 2.5, 5 and 10 mg oral emixustat hydrochloride once daily for 24 months in about 440 patients. The product has Fast Track designation in the...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >